Although GZMB is a serine protease produced by cytotoxic lymphocytes and natural killer cells, typically associated with target cell apoptosis and considered a marker of anti-tumor immunity (21–24), its elevated expression in IBC correlated with immunosuppressive cell activation and an adverse prognosis. This evidence concerns the gene GZMB and inflammatory breast carcinoma.